

GLEN MILLS, PA -- December 8, 2006

Longport, Inc. (OTC PK: LPTI), a medical technology specialist in high-frequency, high-resolution ultrasound imaging, today announced that it had gained additional FDA marketing clearance for its EPISCAN high-resolution ultrasound imaging system.

The expanded clearance, which has the FDA reference number K062571, is summarized by the indications of use statement below and is in addition to the FDA clearance previously obtained under reference number K990238. This clearance will enable Longport to directly market for specific clinical applications as described below.

"The EPISCAN I-200 high-resolution ultrasound system is a specialized system for imaging the skin and underlying soft tissue. It is intended for use by clinicians, or under the direction of physicians for imaging and analysis in research environments as well as clinical settings including medical / surgical dermatology assessment and diagnosis (aesthetic and therapeutic), plastic / reconstructive surgical planning, wound assessment and management, skin assessment for pressure ulcer detection and prevention and superficial musculoskeletal diagnosis."

Paul Wilson, President of Longport commented. "During 2006, Longport's strategy included obtaining regulatory acceptance, embarking on an expanded clinical study program and the publication of study results, as well as continued research and development to enhance our technological base. This deliberate process for gaining recognition for the use of our technology as well as validating the benefits is necessary to establish commercial markets for our products and gain acceptance for the use of diagnostic ultrasound in markets where imaging technology is not firmly established."

About Longport, Inc.

Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high-resolution ultrasound imaging. After several years and a multimillion dollar investment in the technology, Longport has secured patents, copyrights and FDA permission to market. The Company's technology has been used to engineer a unique high-resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com

Forward-looking Information and the Private Securities Litigation Reform Act of 1995

Certain statements in this press release, including statements concerning product development milestones and anticipated events, are "forward-looking statements" within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport's actual results include, among others, uncertainties as to the Company's ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport's 2004 annual report on Form 10-K filed with the Securities and

Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.